Safety of belimumab in association with denosumab in a patient affected by Lupus Erythematosus: a case report

Safety of belimumab in association with denosumab in a patient affected by Lupus Erythematosus: a case report

Authors

  • Marco Scarati Rheumatology Unit. Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino
  • Simone Parisi Rheumatology Unit. Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino
  • Richard Borrelli Rheumatology Unit. Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino
  • Maria Bruzzone Rheumatology Unit. Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino
  • Marta Priora Rheumatology Unit. Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino
  • Clara Lisa Peroni Rheumatology Unit. Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino
  • Enrico Fusaro Rheumatology Unit. Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino

DOI:

https://doi.org/10.7175/cmi.v11i1.1286

Keywords:

Systemic Lupus Erythematosus, Belimumab, Denosumab

Abstract

Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease characterized by multisystemic involvement. Owing to multifactorial etiologies, low bone mineral density (BMD) osteoporosis (OP) and fragility fractures (FFx) have been very frequently documented in these patients. Appropriate treatments to minimize underlying immunologic disease activity remain mandatory, and the development of strategies to prevent and treat important complications as osteoporosis is needed.

We present the clinical case of a female SLE patient treated simultaneously with belimumab (anti-BLyS) for the underlying disease, and denosumab (anti-RANKL) for concomitant severe osteoporosis. As these monoclonal antibodies have been recently introduced into the market, their combination has not been reported in literature yet. In this case, the combined administration proved a viable option for a SLE patient with osteoporosis and bisphosphonates contraindications.

References

Rahman A, Isenberg DA. Systemic lupus erythematosus. N Engl J Med 2008; 358: 929-39; https://doi.org/10.1056/NEJMra071297

Vilas-Boas A, Morais SA, Isenberg DA. Belimumab in systemic lupus erythematosus. RMD Open 2015; 1: e000011; https://doi.org/10.1136/rmdopen-2014-000011

Larosa M, Iaccarino L, Gatto M, et al. Advances in the diagnosis and classification of systemic lupus erythematosus. Expert Rev Clin Immunol 2016; 12: 1309-20 https://doi.org/10.1080/1744666x.2016.1206470

Kuhn A, Bonsmann G, Anders HJ, et al. The diagnosis and treatment of systemic lupus erythematosus. Dtsch Arztebl Int 2015; 112: 423-32; https://doi.org/10.3238/arztebl.2015.0423

Petri M, Orbai AM, Alarcón GS, et al. Derivation and validation of Systemic Lupus International Collaborating Clinics Classification Criteria for Systemic Lupus Erythematosus. Arthritis Rheum 2012; 64: 2677-86; https://doi.org/10.1002/art.34473

Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725; https://doi.org/10.1002/art.1780400928

Yu C, Gershwin ME, Chang C. Diagnostic criteria for systemic lupus erythematosus: a critical review. J Autoimmun 2014; 48-9: 10-3; https://doi.org/10.1016/j.jaut.2014.01.004

Yee CS, Crabtree N, Skan J, et al. Prevalence and predictors of fragility fractures in systemic lupus erythematosus. Ann Rheum Dis 2005; 64: 111-3; https://doi.org/10.1136/ard.2003.018127

Bultink IE, Lems WF. Systemic lupus erythematosus and fractures. RMD Open 2015; 1(Suppl 1): e000069; https://doi.org/10.1136/rmdopen-2015-000069

Rentero ML, Amigo E, Chozas N, et al; GHDP study group. Prevalence of fractures in women with rheumatoid arthritis and/or systemic lupus erythematosus on chronic glucocorticoid therapy. BMC Musculoskelet Disord 2015; 16: 300; https://doi.org/10.1186/s12891-015-0733-9

Cramarossa G, Urowitz MB, Su J, et al. Prevalence and associated factors of low bone mass in adults with systemic lupus erythematosus. Lupus 2016 Aug 13 [Epub ahead of print]; https://doi.org/10.1177/0961203316664597

Carli L, Tani C, Spera V, et al. Risk factors for osteoporosis and fragility fractures in patients with systemic lupus erythematosus. Lupus Sci Med 2016; 3: e000098; https://doi.org/10.1136/lupus-2015-000098

Salman-Monte TC, Torrente-Segarra V, Muñoz-Ortego J, et al. Prevalence and predictors of low bone density and fragility fractures in women with systemic lupus erythematosus in a Mediterranean region. J Rheumatol Int 2015; 35: 509-15; https://doi.org/10.1007/s00296-014-3087-y

Bultink IEM. Osteoporosis and fractures in systemic lupus erythematosus. Arthritis Care Res 2012; 64: 2-8; https://doi.org/10.1002/acr.20568

Di Munno O, Mazzantini M, Delle Sedie A, et al. Risk factors for osteoporosis in female patients with systemic lupus erythematosus. Lupus 2004; 3: 724-30; https://doi.org/10.1191/0961203303lu1097oa

Vincent FB, Morand EF, Schneider P, et al. The BAFF/APRIL system in SLE pathogenesis. Nat Rev Rheumatol 2014; 10: 365-73; https://doi.org/10.1038/nrrheum.2014.33

Collins CE, Dall’Era M, Kan H, et al. Response to belimumab among patients with systemic lupus erythematosus in clinical practice settings: 24-month results from the OBSErve study in the USA. Lupus Sci Med 2016; 3: e000118; https://doi.org/10.1136/lupus-2015-000118

Hanley DA, Adachi JD, Bell A, et al. Denosumab: mechanism of action and clinical outcomes. Int J Clin Pract. 2012; 66: 1139-46; https://doi.org/10.1111/ijcp.12022

Suresh E, Abrahamsen B. Denosumab: a novel antiresorptive drug for osteoporosis. Cleve Clin J Med 2015; 82: 105-14; https://doi.org/10.3949/ccjm.82a.13173

Törring O. Effects of denosumab on bone density, mass and strength in women with postmenopausal osteoporosis. Ther Adv Musculoskelet Dis 2015; 7: 88-102; https://doi.org/10.1177/1759720X15579189

Downloads

Published

2017-04-06

Issue

Vol. 11 No. 1 (2017)

Section

Case report

License

Authors who publish with this journal agree to the following terms:
    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution Non-Commercial 4.0 Licence that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
    2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. The Publication Agreement can be downloaded here, and should be signed by the Authors and sent to the Publisher when the article has been accepted for publication in this journal.
    3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
    4. Authors are permitted to post their work online after publication (the article must link to publisher version, in html format)